QuidelOrtho Corp (QDEL)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $736.90M
Last updated: Nov 17, 2026 at 11:06 AM ET
QuidelOrtho Corp (QDEL) Earnings: Report Dates and Results
QuidelOrtho (QDEL) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, QuidelOrtho reported EPS of $0.31, above the $0.18 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
QDEL has an expected report date of Feb 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 43.5% below the $0.46 reported for the quarter ended Dec 31, 2025.
QDEL Earnings Call
The latest QDEL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, QDEL beat 29, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $618.90M, down 11.6% from $699.90M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.31 | $0.18 | $0.18 - $0.18 | +72.22% | Beat | -61.3% | 1 | 0 up, 1 down | Nov 3, 2026 | $618.90M |
| Jun 30, 2026 | $0.13 | -$0.04 | -$0.05 - -$0.04 | +425.00% | Beat | +8.3% | 2 | 0 up, 1 down | Aug 6, 2026 | $630.90M |
| Mar 31, 2026 | -$0.04 | $0.36 | $0.35 - $0.56 | -111.11% | Miss | -105.4% | 4 | 0 up, 1 down | May 5, 2026 | $619.80M |
| Dec 31, 2025 | $0.46 | $0.42 | $0.39 - $0.45 | +9.52% | Beat | -27.0% | 6 | 0 up, 1 down | Feb 11, 2026 | $723.60M |
| Sep 30, 2025 | $0.80 | $0.51 | $0.37 - $0.57 | +56.86% | Beat | -5.9% | 6 | 1 up, 3 down | Nov 5, 2025 | $699.90M |
| Jun 30, 2025 | $0.12 | $0.01 | -$0.09 - $0.07 | N/A | N/A | N/A | 6 | 0 up, 0 down | Aug 5, 2025 | $613.90M |
| Mar 31, 2025 | $0.74 | $0.59 | $0.46 - $0.67 | +25.42% | Beat | +68.2% | 7 | 0 up, 2 down | May 7, 2025 | $692.80M |
| Dec 31, 2024 | $0.63 | $0.58 | $0.48 - $0.68 | +8.62% | Beat | -46.2% | 8 | 1 up, 0 down | Feb 12, 2025 | $707.80M |
| Sep 30, 2024 | $0.85 | $0.32 | $0.22 - $0.43 | +165.63% | Beat | -5.6% | 8 | 0 up, 0 down | Nov 7, 2024 | $727.10M |
| Jun 30, 2024 | -$0.07 | -$0.24 | -$0.35 - -$0.07 | +70.83% | Beat | -126.9% | 7 | 0 up, 0 down | Jul 31, 2024 | $637.00M |
| Mar 31, 2024 | $0.44 | $0.40 | $0.25 - $0.56 | +10.00% | Beat | -75.6% | 7 | 0 up, 0 down | May 8, 2024 | $711.00M |
| Dec 31, 2023 | $1.17 | $2.06 | $1.87 - $2.23 | -43.20% | Miss | -33.5% | 8 | 0 up, 0 down | Feb 13, 2024 | $742.60M |
| Sep 30, 2023 | $0.90 | $0.56 | $0.40 - $1.10 | +60.71% | Beat | -51.4% | 8 | 3 up, 0 down | Nov 1, 2023 | $744.00M |
| Jun 30, 2023 | $0.26 | $0.26 | $0.02 - $0.42 | 0.00% | In line | -88.9% | 8 | 1 up, 0 down | Aug 8, 2023 | $665.10M |
| Mar 31, 2023 | $1.80 | $1.43 | $1.31 - $1.95 | +25.87% | Beat | -84.6% | 8 | 3 up, 0 down | May 3, 2023 | $846.10M |
| Dec 31, 2022 | $1.76 | $1.42 | $1.31 - $1.61 | +23.94% | Beat | -75.9% | 8 | 0 up, 0 down | Feb 15, 2023 | $866.50M |
| Sep 30, 2022 | $1.85 | $0.69 | $0.49 - $1.17 | +168.12% | Beat | -65.5% | 7 | 3 up, 0 down | Nov 2, 2022 | $783.80M |
| Jun 30, 2022 | $2.34 | $2.68 | N/A | -12.69% | Miss | +212.0% | N/A | 1 up, 0 down | Aug 4, 2022 | $613.40M |
| Mar 31, 2022 | $11.66 | $9.43 | $7.93 - $11.75 | +23.65% | Beat | +166.2% | 5 | 2 up, 0 down | May 4, 2022 | $1.00B |
| Dec 31, 2021 | $7.29 | $5.61 | $4.31 - $6.76 | +29.95% | Beat | -34.1% | 5 | 0 up, 0 down | Feb 17, 2022 | $636.87M |
| Sep 30, 2021 | $5.36 | $2.30 | $0.82 - $5.39 | +133.04% | Beat | -7.3% | 5 | N/A | Nov 4, 2021 | $509.80M |
| Jun 30, 2021 | $0.75 | $1.19 | $0.92 - $1.60 | -36.97% | Miss | -59.7% | 6 | N/A | Aug 5, 2021 | $176.60M |
| Mar 31, 2021 | $4.38 | $4.68 | $3.93 - $5.07 | -6.41% | Miss | +259.0% | 6 | N/A | May 6, 2021 | $375.34M |
| Dec 31, 2020 | $11.07 | $10.10 | $9.68 - $10.47 | +9.60% | Beat | +1007.0% | 6 | N/A | Feb 18, 2021 | $809.20M |
| Sep 30, 2020 | $5.78 | $4.70 | $4.09 - $5.20 | +22.98% | Beat | +725.7% | 6 | N/A | Oct 29, 2020 | $476.06M |
| Jun 30, 2020 | $1.86 | $1.09 | $0.84 - $1.81 | +70.64% | Beat | +416.7% | 6 | N/A | Jul 30, 2020 | $201.75M |
| Mar 31, 2020 | $1.22 | $0.95 | $0.86 - $1.16 | +28.42% | Beat | +34.1% | 6 | N/A | May 6, 2020 | $174.65M |
| Dec 31, 2019 | $1.00 | $0.82 | $0.74 - $0.92 | +21.95% | Beat | +25.0% | 6 | N/A | Feb 12, 2020 | $152.18M |
| Sep 30, 2019 | $0.70 | $0.64 | $0.59 - $0.70 | +9.38% | Beat | +18.6% | 6 | N/A | Oct 30, 2019 | $126.49M |
| Jun 30, 2019 | $0.36 | $0.37 | N/A | -2.70% | Miss | 0.0% | 5 | N/A | Aug 8, 2019 | $108.25M |
| Mar 31, 2019 | $0.91 | $1.05 | $0.99 - $1.07 | -13.33% | Miss | -29.5% | 5 | N/A | May 8, 2019 | $147.97M |
| Dec 31, 2018 | $0.80 | $0.63 | $0.43 - $0.69 | +26.98% | Beat | +247.8% | 6 | N/A | Feb 13, 2019 | $132.59M |
| Sep 30, 2018 | $0.59 | $0.49 | $0.39 - $0.59 | +20.41% | Beat | +227.8% | 7 | N/A | Nov 6, 2018 | $117.40M |
| Jun 30, 2018 | $0.36 | $0.27 | $0.15 - $0.30 | +33.33% | Beat | N/A | 6 | N/A | Aug 7, 2018 | $103.16M |
| Mar 31, 2018 | $1.29 | $0.98 | $0.94 - $1.17 | +31.63% | Beat | +186.7% | 7 | N/A | May 8, 2018 | $169.14M |
| Dec 31, 2017 | $0.23 | $0.20 | -$0.14 - $0.40 | +15.00% | Beat | N/A | 4 | N/A | Feb 21, 2018 | $114.89M |
| Sep 30, 2017 | $0.18 | $0.13 | N/A | +38.46% | Beat | +80.0% | 5 | N/A | Nov 1, 2017 | $50.89M |
| Jun 30, 2017 | -$0.12 | -$0.09 | N/A | -33.33% | Miss | N/A | 6 | N/A | Jul 26, 2017 | $38.27M |
| Mar 31, 2017 | $0.45 | $0.29 | N/A | +55.17% | Beat | +2150.0% | N/A | N/A | Apr 24, 2017 | $73.69M |
| Dec 31, 2016 | -$0.06 | $0.02 | N/A | -400.00% | Miss | N/A | N/A | N/A | Feb 8, 2017 | $52.81M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.12, up 14.6% from the year before. It was -$0.05 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.12 | +14.6% |
| Dec 31, 2024 | $1.85 | -55.2% |
| Dec 31, 2023 | $4.13 | -76.5% |
| Dec 31, 2022 | $17.61 | -1.0% |
| Dec 31, 2021 | $17.78 | -10.8% |
| Dec 31, 2020 | $19.93 | +571.0% |
| Dec 31, 2019 | $2.97 | -2.3% |
| Dec 31, 2018 | $3.04 | +310.8% |
| Dec 31, 2017 | $0.74 | N/A |
| Dec 31, 2016 | -$0.05 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,482 | 8 | |
| 2026Q2 | Jun 30, 2026 | 3,620 | 6 | |
| 2026Q1 | Mar 31, 2026 | 3,945 | 8 | |
| 2025Q4 | Dec 31, 2025 | 7,746 | 13 | |
| 2025Q3 | Sep 30, 2025 | 3,592 | 7 | |
| 2025Q2 | Jun 30, 2025 | 6,207 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,373 | 12 | |
| 2024Q4 | Dec 31, 2024 | 6,571 | 13 |
2026Q3 Earnings Call
Opening remarks
Sanjeev Sharma Vice President of Investor Relations Good afternoon, everyone, and thank you for joining us on our earnings call. With us today, we have Brian Blaser, our President and Chief Executive Officer; and Micah Young, our Chief Financial Officer. This conference call is being simultaneously webcast on the IR section of our website. To assist in the presentation, we also posted supplemental information on the Investor Relations page that will be referenced throughout this call. Please note that this conference call and supplemental information contain forward-looking statements, including the company's expectations, plans, financial guidance and various strategic initiatives. We assume no obligation to update any forward-looking statements, except as required by law. These statements are made as of today and are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in these statements. Please refer to our SEC filings for a description of potential risks. In addition, today's call includes discussion of certain non-GAAP financial measures. Tables reconciling these non-GAAP measures to their most directly comparable GAAP measures are available in our earnings release and supplemental information on the Investor Relations page of our website. Lastly, unless stated otherwise, all year-over-year revenue growth rates given on today's call are on a constant currency basis. With that, I would like to turn the call over to our President and CEO, Brian Blaser.
Brian Blaser President and Chief Executive Officer Thanks, Sanjeev, and good afternoon, everyone. I'd like to begin with 3 important takeaways from the quarter. First, the underlying performance of our business remains resilient. Labs and immunohematology, which represents 70% to 75% of our revenue, excluding China, delivered low to mid-single-digit organic growth. Second, our reported results continue to reflect 2 significant near-term headwinds, the impact of China's now finalized nationwide IVD pricing guidelines and the softer respiratory testing environment in point of care. Third, we are acting decisively and launching a new cost transformation and enterprise restructuring program designed to improve profitability and cash generation while evolving our operating model around the distinct needs of our customers and markets. These actions are intended to strengthen execution today and position QuidelOrtho for sustainable, profitable growth over the long term. Turning to our third quarter results. Total reported revenue was $619 million, down 12% from last year. Revenue increased 3%, excluding China, respiratory and the prior year contribution from the U.S. Donor Screening business, which we are winding down. Labs revenue outside China grew 4%, supported by the strength and durability of our customer relationships and large global installed base. Immunohematology revenue outside China increased 3%, reflecting steady demand across key markets and our strong position in the segment. Together, these results reinforce an important point. The underlying fundamentals of our business remain healthy.
Frequently Asked Questions About QDEL
When is QuidelOrtho's next earnings date?
QuidelOrtho's next earnings report is expected for Feb 9, 2027.
Did QDEL beat earnings estimates last quarter?
Yes. QuidelOrtho reported EPS of $0.31 for the quarter ended Sep 30, 2026, above the $0.18 estimate, a 72.22% surprise.
What EPS do analysts expect from QDEL next quarter?
The consensus EPS estimate for QuidelOrtho for the quarter ending Dec 31, 2026 is $0.26 from 5 analysts, with estimates from $0.25 to $0.27.
How often does QDEL beat earnings estimates?
QuidelOrtho beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +81.52%.
QDEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts